Induction of antiviral gene expression by cyclosporine A, but not inhibition of cyclophilin A or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell line

• Published in: Antiviral research 2023-11, Vol.219, p.105730-105730, Article 105730
• Main Authors: Mamatis, John E., Gallardo-Flores, Carla E., Sangwan, Ujjwal, Tooley, Trinity H., Walsh, Taylor, Colpitts, Che C.
• Format: Article
• Language: English
• Subjects: Coronavirus; Cyclosporine A; Drug repurposing; Host-targeting antiviral; Innate immunity
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2023.105730

The development of antivirals with an extended spectrum of activity is an attractive possibility to protect against future emerging coronaviruses (CoVs). Cyclosporine A (CsA), a clinically approved immunosuppressive drug, has established antiviral activity against diverse unrelated viruses, including several CoVs. However, its antiviral mechanisms of action against CoV infection have remained elusive, precluding the rational design of non-immunosuppressive derivatives with improved antiviral activities. In this study, we evaluated the mechanisms of CsA against HCoV-229E infection in a human lung epithelial cell line. We demonstrate that the antiviral activity of CsA against HCoV-229E is independent of classical CsA target proteins, cyclophilin A or B, which are not required host factors for HCoV-229E in A549 cells. Instead, CsA treatment induces expression of antiviral genes in a manner dependent on interferon regulatory factor 1, but independent of classical interferon responses, which contributes to its inhibitory effect against HCoV-229E infection. Our results also point to a role for the HCoV-229E nucleoprotein in antagonizing activation of type I interferon, but we show that CsA treatment does not affect evasion of innate immune signalling pathways by HCoV-229E. Overall, our findings further the understanding of the antiviral mechanisms of CsA against CoV infection and highlight a novel immunomodulatory strategy to inhibit CoV infection that may inform future drug development efforts. •CsA inhibits HCoV-229E infection in A549 lung epithelial cells.•Cyclophilin (Cyp) A or B are not host factors for HCoV-229E in A549 cells.•CsA induces IRF1-dependent antiviral gene expression to inhibit HCoV-229E.•CsA promotes nuclear localization of IRF1.